SILVER SPRING, Md., April 11, 2012 /PRNewswire/ --Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to announce that HDS has entered into an agreement with DS Healthcare Limited to assist in introducing Clotamin to the UK/EU market.
Under terms of the agreement, DS Healthcare will evaluate the Clotamin formulation and claims against the European Union Food Supplement Directive, the Nutritional Health Claims Directive, and Food Labeling Regulations to determine any specific actions and timeline required to introduce Clotamin to the UK/EU market.
"The UK and European Union market represent an enormous opportunity to expand Clotamin distribution into new territories and reach millions of new potential Clotamin users. The agreement with DS Healthcare is the first step towards achieving that goal," stated Mackie A. Barch, CEO of Sunpeaks Ventures. "We intend to fully utilize their extensive technical, commercial, and regulatory expertise to build and launch the Clotamin brand across Europe."
DS Healthcare Limited are experts in the UK/EU natural healthcare sector and currently distribute numerous products to the market. The company also provides consultancy services to select healthcare businesses, including pet and equine, right across the entire supply chain from new product development to marketing.
About Sunpeaks Ventures, Inc.
Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.
For additional information, please visit www.sunpeaksventures.com.
Contact: Financial Insights 888-248-8491 or email@example.com
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
SOURCE Sunpeaks Ventures, Inc.